Feb 4 (Reuters) - Cigna Corp's Express Scripts has settled the U.S. ‌Federal ​Trade Commission's claims its insulin pricing ‌practices violated antitrust and consumer protection laws, and agreed to ...

ROURKELA: Displaying remarkable efficiency, the Biju Patnaik University of Technology (BPUT), Rourkela on Thursday night ...

Cigna reported 11% revenue growth for 2025. Company executives focused on several key issues in its call with investors: its settlement with the Federal Trade Commission, a transformation announced ...

Cigna is hoping the settlement it reached with regulators paired with recent legislation will mollify calls to reform PBMs — without affecting Express Scripts’ profitability.

According to Express Scripts, its new pharmacy benefits model, first announced in October 2025, could lower brand name ...

Cigna's top brass said that the company has anticipated a "clearing event" in the pharmacy benefit management industry, and that its new model aligns with regulators' push toward greater transparency.

Express Scripts agreed to overhaul its business model, ensuring patients pay the lowest available price for medications and ...

The agreement orders Express Scripts to offer plan members the lowest available cost for medicine like insulin rather than ...

After years of trying, Congress is finally on the verge of passing legislation aimed at lowering prescription drug prices by targeting the intermediaries that help negotiate them.

Health insurance providers are temporarily allowing early and emergency prescription refills across North Carolina as severe winter weather threatens the state.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The lawsuit alleges that insulin ...

Delaware Attorney General Kathy Jennings is suing several drug manufacturers and pharmacy benefit managers for reported insulin price gouging, following similar legal action taken by other states in ...